Company news
AXIM Biotechnologies, Inc. news in 2020
AXIM Biotechnologies, Inc.'s news releases, calls and decks from 2020, newest first.
AXIM® Biotechnologies Completes Successful Covid-19 Live Virus Test and Files Amended EUA for Portable 10 Minute Rapid Diagnostic Test for Neutralizing Antibodies
December 15, 2020
AXIM® Biotechnologies to Present at the 13th Annual LD Micro Main Event Investor Conference on Monday, December 14
December 14, 2020
AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19 Test-Focused Patent Application
December 3, 2020
AXIM® Biotechnologies Applauds Vaccine Producers, Highlights Need for Rapid Antibody Testing to Ensure Immunity
November 10, 2020
AXIM® Biotechnologies Issues Update Letter to Shareholders
October 28, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)
October 6, 2020
AXIM® Biotechnologies Files Patent for Virus Binding Recombinant Protein for SARS-CoV-2 (COVID-19) and Begins Manufacturing
September 30, 2020
AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 COVID-19
September 29, 2020
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1
September 22, 2020
AXIM® Biotechnologies Files Emergency Use Authorization With the FDA for First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies
September 16, 2020
AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test
August 24, 2020
Sapphire Biotech, Subsidiary of AXIM® Biotechnologies, Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute
August 11, 2020
AXIM® Biotechnologies Applies for FDA Emergency Use Approval (EUA) for High Throughput, Patent-Pending Neutralizing Antibody Diagnostic Test for COVID-19
August 5, 2020
AXIM® Biotechnologies Releases Rapid NeuCovix™ Test Results Showing Strong Agreement with COVID-19-Based Neutralization Tests
July 23, 2020
AXIM® Biotechnologies Welcomes Former Secretary of Veterans Affairs Peter O'Rourke to Company’s Board of Directors
July 21, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Unveils World’s First COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies and Files Pre-Emergency Use Authorization
July 21, 2020
AXIM® Biotechnologies Unveils First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies and Files Pre-Emergency Use Authorization with the FDA
July 15, 2020
AXIM® Biotechnologies Appoints Dr. Alim Seit-Nebi as Chief Technology Officer of Subsidiary Sapphire Biotech
June 9, 2020
AXIM® Biotechnologies Begins Pre-Clinical Pharmacokinetic Animal Drug Studies on its Cancer Drug Compound SPX-1009
June 1, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Expands Research Division and Announces Dr. Sergei Svarovsky as Chief Scientific Officer of Subsidiary Sapphire Biotech
May 28, 2020
AXIM® Biotechnologies Expands Research Division and Announces Dr. Sergei Svarovsky as Chief Scientific Officer of Subsidiary Sapphire Biotech
May 27, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for Unique Early Detection Cancer Biomarker
May 21, 2020
AXIM® Biotechnologies Files for Patent for Unique Biomarker for Early Detection of Cancer in Blood
May 18, 2020
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files New U.S. Patent Application for Water-Soluble Cannabinoid Molecules
May 5, 2020
AXIM® Biotechnologies Files New U.S. Patent Application for Water-Soluble Cannabinoid Molecules
April 28, 2020
AXIM® Biotechnologies Receives New U.S. Patent Issuance for Chewing Gum Comprising Cannabinoids and Nicotine to Treat or Alleviate Tobacco Smoking
April 7, 2020
AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on New Compound Proving Tenfold Greater Inhibition of Tumor Metastasis Than Parent Compound
March 24, 2020
AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.
March 18, 2020
AXIM® Biotechnologies Nutraceutical Division Announces Launch of CBD-Based Gum for Professional and Amateur Golfers
February 26, 2020
Axim® Biotechnologies Completes First Phase of Pharmacokinetic Clinical Study on Cannabinoid-Based Gum With Dronabinol
February 18, 2020
AXIM® Biotechnologies Nutraceutical Division Announces Launch of Cannabinoid-Based Workout Gum and Other Upcoming Product Launches
February 12, 2020
AXIM® Biotechnologies Acquiree Sapphire Biotech, Inc. Signs Sponsored Research Agreement with Arizona State University to Develop Metastatic Cancer Inhibitor
February 10, 2020
AXIM® Biotechnologies Acquiree Sapphire Biotech, Inc. Signs License Agreement to Exclusively License Patent Rights in Cancer Technology
January 22, 2020
AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.
January 8, 2020
Decks in 2020
- Investor Presentation (May 2020)
Investor deck · 27 slides · May 2020